Menu
×
Thị trường 24h
Chính sách
Dự án
Cao ốc văn phòng
Khu căn hộ cao cấp
Khu du lịch nghỉ dưỡng
Khu công nghiệp
Khu dân cư
Biệt thự
Trung tâm thương mại
Đất chia lô
Căn hộ chung cư
Kiến thức
Góc nhìn chuyên gia
Phân tích Nhận định
Góc pháp luật
Phong thuỷ
Nhà đẹp
Nội thất
Ngoại thất
Khám phá - Trải nghiệm
Bầu chọn
English
AKWEL: NET INCOME OF €24.2 MILLION IN 2024
Globe Newswire
Notified -
Eight in ten dog lovers take as much care over choosing their pet’s dinner as they do with their own meals, new research has revealed
Globe Newswire
Notified -
Love on Tap: Heineken® Launches Dating App for Bars to Help Young Adults Spice Up Their Social Lives
Globe Newswire
Notified -
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
Globe Newswire
Notified -
Axi launches ‘Four Years’ campaign with Manchester City stars
Globe Newswire
Notified -
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
Globe Newswire
Notified -
Appian completes sale of MVV to Baiyin Nonferrous for US$420 million
Globe Newswire
Notified -
Mitolyn Reviews (NEW MEDICAL ALERT): Doctor Uncovers the Truth About This Bio-Energy Hack for Natural Weight Loss
Globe Newswire
Notified -
Thị trường 24h
OPEN Health Appoints Matt D’Auria as Chief Executive Officer to Drive Innovation and Growth
Notified -
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
Saudi National Pavilion at London Design Biennale 2025: "Good Water" Invites us to Rethink Our Relationship With Water
Axi launches ‘Four Years’ campaign with Manchester City stars
Khám phá & trải nghiệm
Prime Biome (INVESTIGATIVE REPORT): Does This Trending Gut Reset Supplement Actually Deliver Real Results?
Gluco Extend Reviews (2025): Investigative Report on Its Blood Sugar & Insulin Support Benefits In 2025
Bombardier Defense Announces Order of Two Challenger 650 Aircraft Destined for Intelligence, Surveillance and Reconnaissance missions in Australia
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
